Intricately woven, cancer’s complicated nature hinders true understanding. Within its tightly threaded patterns are answers to your most pressing questions: Where does a new disease state begin? Can I find the mutations that drive relapse, treatment response, or drug resistance? And which cells harbor these changes and carry them forward as an illness evolves?
Today, we’re unveiling our newest instrument, which unravels these complexities to unlock the ground truth of cancer through response, relapse, and remission.
Empowering Faster, More Successful Development of Precision Cancer Therapies
The new TapestriⓇ Single-cell Multi-omics Solution is the most comprehensive single-cell multi-omics platform on the market. With a new instrument, multi-omics reagent kits, TotalSeq-D™ antibody content from BioLegend, and visualization software, the complete package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half.
Every year, the pharmaceutical industry loses $50 billion on failed clinical trials and ineffective drugs. Bulk sequencing erases cancer’s fundamental units, individual cells, while multi-omics technologies can’t delineate key somatic driver mutations within those cells.
As the first and only one to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can now illuminate the communication pathway all the way from the blueprint of life in the center of the cell — DNA — to the exterior of the cell via surface proteins, without inference or conjecture. The integrated solution offers deeper insight into therapy resistance and relapse to empower faster, more successful development of precision cancer therapies and saves the industry billions in drug development costs.
Our novel offering has been adopted by marquee NCI Cancer Centers, including MD Anderson Cancer Center (MDACC), Memorial Sloan Kettering Cancer Center (MSK), and the University of California, San Francisco (UCSF). Already, the new solution has been leveraged to support numerous peer-reviewed studies, validating its value to the industry. Most recently, a Nature publication from MSK leveraged the Tapestri Platform’s DNA + Protein capabilities to reveal the clonal complexity driving disease progression in myeloid malignancies, while a Nature Communications publication from MDACC illustrated the single-cell atlas of AML with multi-omics, describing the clonality underlying therapeutic resistance.
At Mission Bio, we’re helping unravel the inherent complexity of cancer, to untangle the insights you need to develop more precise therapies, more quickly, to save more patient lives. We look forward to advancing this mission with the latest Tapestri Platform.
Single-cell, Beyond the Lab
That’s where we come in. The Tapestri® Platform is the first-ever single-cell multi-omics platform capable of detecting DNA and protein changes simultaneously from the same cell. With this insight, we can see the past, present, and future of each person’s cancer — determine how it evolved, see a snapshot of it in time, and begin to predict treatment response to help develop new therapeutic approaches aimed at preventing disease evolution and relapse.
On a Mission to Eliminate Cancer
While the world directs all attention and resources at fighting COVID-19, research into preventative care, health monitoring, and a cure for cancer has taken a back seat. The hard truth is that cancer is not sheltering in place, and at the end of this, we’re going to see increased late-stage cancer cases and mortality rates.
We are on a mission to help our customers eliminate cancer. Over the past year, we have significantly advanced our efforts to support drug development through clinical trials and the translation of research into novel biomarkers, as demonstrated by our ongoing work with NCI cancer centers and leading biopharma companies. With support from Novo Growth, Soleus Capital, Mayfield, Cota Capital, Agilent, and Labcorp, we’re able to scale the Tapestri Platform to expand our support of clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.
At Mission Bio, we envision a world with a different relationship to complex diseases like cancer: a world where cancer is manageable, even curable. With this latest capital, we’re on track to make that vision a reality.